JPMorgan Chase & Co. Decreases Stake in Voyager Therapeutics, Inc. (NASDAQ:VYGR)

JPMorgan Chase & Co. lessened its holdings in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 7.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 241,634 shares of the company’s stock after selling 20,300 shares during the period. JPMorgan Chase & Co. owned 0.44% of Voyager Therapeutics worth $1,370,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of VYGR. Geode Capital Management LLC grew its position in shares of Voyager Therapeutics by 0.6% in the third quarter. Geode Capital Management LLC now owns 1,079,509 shares of the company’s stock valued at $6,316,000 after purchasing an additional 6,740 shares in the last quarter. Barclays PLC grew its holdings in Voyager Therapeutics by 55.8% in the 3rd quarter. Barclays PLC now owns 104,462 shares of the company’s stock valued at $612,000 after buying an additional 37,398 shares in the last quarter. Allspring Global Investments Holdings LLC grew its holdings in Voyager Therapeutics by 23.9% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 39,313 shares of the company’s stock valued at $223,000 after buying an additional 7,573 shares in the last quarter. Rhumbline Advisers raised its holdings in shares of Voyager Therapeutics by 3.4% during the 4th quarter. Rhumbline Advisers now owns 71,497 shares of the company’s stock worth $405,000 after acquiring an additional 2,354 shares during the period. Finally, American Century Companies Inc. boosted its position in shares of Voyager Therapeutics by 8.1% during the 4th quarter. American Century Companies Inc. now owns 122,726 shares of the company’s stock valued at $696,000 after acquiring an additional 9,190 shares during the last quarter. Institutional investors and hedge funds own 48.03% of the company’s stock.

Voyager Therapeutics Trading Down 1.7 %

VYGR stock opened at $3.47 on Friday. The business’s fifty day moving average price is $3.65 and its 200 day moving average price is $5.19. Voyager Therapeutics, Inc. has a 12-month low of $2.75 and a 12-month high of $9.55. The company has a market capitalization of $191.57 million, a PE ratio of 4.89 and a beta of 1.02.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings results on Tuesday, March 11th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.24). Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. The business had revenue of $4.39 million for the quarter, compared to analysts’ expectations of $16.58 million. During the same quarter last year, the company earned $1.25 earnings per share. Research analysts predict that Voyager Therapeutics, Inc. will post -0.91 EPS for the current fiscal year.

Insider Buying and Selling

In other Voyager Therapeutics news, CEO Alfred Sandrock sold 10,885 shares of the business’s stock in a transaction on Wednesday, April 2nd. The shares were sold at an average price of $3.43, for a total value of $37,335.55. Following the completion of the transaction, the chief executive officer now owns 430,931 shares in the company, valued at $1,478,093.33. The trade was a 2.46 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 4.53% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of brokerages have commented on VYGR. HC Wainwright reaffirmed a “buy” rating and set a $30.00 target price on shares of Voyager Therapeutics in a research note on Tuesday, April 8th. Wells Fargo & Company set a $10.00 price target on shares of Voyager Therapeutics and gave the company an “overweight” rating in a research report on Wednesday, March 12th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Voyager Therapeutics in a research report on Wednesday, March 12th. Canaccord Genuity Group reduced their target price on Voyager Therapeutics from $14.00 to $12.00 and set a “buy” rating on the stock in a research report on Thursday, March 13th. Finally, Wedbush reaffirmed an “outperform” rating on shares of Voyager Therapeutics in a research note on Wednesday, March 12th. One research analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Voyager Therapeutics has a consensus rating of “Buy” and an average price target of $13.97.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.